Yes, you can expect to recover your muscle strength with appropriate treatment.
For early mixed connective tissue disease (MCTD) with mild myositis and rising CK, muscle strength recovery is highly favorable with prompt immunosuppressive therapy, and the prognosis for MCTD-associated myositis is generally better than other forms of inflammatory myopathy.
Why Recovery is Expected
The evidence strongly supports muscle recovery in your specific situation:
MCTD myositis responds well to treatment: Research shows that myositis patients with anti-U1-RNP antibodies (which you have) demonstrate "marked improvements in muscle strength" with significantly higher remission rates at 1 and 2 years compared to other forms of immune-mediated myositis 1. In fact, corticosteroid treatment was successfully withdrawn in 6 of 7 anti-RNP-positive patients due to remission 2.
Early disease has better outcomes: Your presentation as "early" disease with "mild" myositis is prognostically favorable. Studies show that anti-RNP-positive patients typically have milder histopathological muscle changes and achieve rapid improvement on moderate doses of corticosteroids 2.
Recent case series confirm good responses: A 2025 study of MCTD myositis patients showed "consistently favorable" therapeutic responses overall, with no deaths during observation 3. Another 2025 case demonstrated "progressive improvement in muscle strength and normalisation of muscle enzyme levels" over six months with appropriate treatment 4.
Treatment Approach for Muscle Recovery
Based on current guidelines for inflammatory myositis 5, here's what you should receive:
Initial therapy (for mild-moderate disease with rising CK):
- High-dose corticosteroids (prednisone 0.5-1 mg/kg/day) concurrent with a steroid-sparing agent from the start
- Steroid-sparing options: methotrexate, azathioprine, or mycophenolate mofetil
- This dual approach from the beginning prevents prolonged corticosteroid exposure
Important caveat about G6PD deficiency: While not directly addressed in the myositis guidelines, your G6PD deficiency means you should avoid certain medications that can trigger hemolysis. However, the standard myositis treatments (corticosteroids, methotrexate, azathioprine, mycophenolate) are generally safe. Your rheumatologist should verify compatibility with your G6PD status.
Monitoring Your Recovery
Track these markers 6:
- CK levels: Should normalize as muscle inflammation resolves
- Muscle strength testing: Objective measurement of proximal muscle groups
- Inflammatory markers: ESR and CRP
- Functional ability: Return to daily activities
Timeline Expectations
- Initial improvement: Most anti-RNP-positive patients show rapid improvement within weeks to months on moderate corticosteroid doses 2
- Sustained remission: Studies show successful corticosteroid withdrawal is achievable, with 6 of 7 anti-RNP patients achieving remission 2
- Full recovery: Case reports demonstrate complete recovery over 6-12 months with appropriate maintenance therapy 4
Critical Monitoring Points
Watch for these features that could indicate more intensive treatment needs 3:
- Atypical weakness patterns (face, neck, wrist, fingers) - present in some MCTD cases
- Dysphagia or respiratory muscle involvement
- Cardiac involvement (check troponin, ECG if symptoms develop)
- Persistently elevated or rising CK despite treatment
If you develop severe weakness limiting self-care, require hospitalization, or show evidence of myocardial involvement, more aggressive therapy (IV methylprednisolone, IVIG, or rituximab) may be needed 6.
Bottom Line
Your combination of early MCTD, mild myositis, and anti-RNP positivity places you in a favorable prognostic category. With prompt initiation of corticosteroids plus a steroid-sparing agent, muscle strength recovery is not only possible but expected. The key is starting treatment early (which you're doing) and maintaining close rheumatologic follow-up to adjust therapy based on your response.